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Abstract
Specific targeting of tumor cells is an important goal for the design of nanotherapeutics for the
treatment of cancer. Recently, viruses have been explored as nano-containers for specific targeting
applications, however these systems typically require modification of the virus surface using
chemical or genetic means to achieve tumor-specific delivery. Interestingly, there exists a subset of
viruses with natural affinity for receptors on tumor cells that could be exploited for
nanotechnology applications. For example, the canine parvovirus (CPV) utilizes transferrin
receptors (TfRs) for binding and cell entry into canine as well as human cells. TfRs are over-
expressed by a variety of tumor cells and are widely being investigated for tumor-targeted drug
delivery. We explored whether the natural tropism of CPV to TfRs could be harnessed for
targeting tumor cells. Towards this goal, CPV virus-like particles (VLPs) produced by expression of
the CPV-VP2 capsid protein in a baculovirus expression system were examined for attachment of
small molecules and delivery to tumor cells. Structural modeling suggested that six lysines per VP2
subunit are presumably addressable for bioconjugation on the CPV capsid exterior. Between 45
and 100 of the possible 360 lysines/particle could be routinely derivatized with dye molecules
depending on the conjugation conditions. Dye conjugation also demonstrated that the CPV-VLPs
could withstand conditions for chemical modification on lysines. Attachment of fluorescent dyes
neither impaired binding to the TfRs nor affected internalization of the 26 nm-sized VLPs into
several human tumor cell lines. CPV-VLPs therefore exhibit highly favorable characteristics for
development as a novel nanomaterial for tumor targeting.
Background
Conventional chemotherapy for treating cancer is non-
selective and therefore associated with toxic side effects,
limiting a drug's therapeutic index [1-4]. Targeted delivery
of drugs is ideal in order to enhance therapeutic benefit as
well as reduce systemic toxicity. Recently the development
of novel methods to achieve specific tumor targeting has
received significant focus [5,6]. Strategies investigated
towards this goal include "smart" tissue-specific particles
such as liposomes [7], antibodies [8,9], viral particles [10-
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12] and dendrimers [13] that are comprised of targeting
moieties and cytotoxic drugs.
Currently virus-based nanoparticles (VBNPs) are being
extensively investigated for nanobiotechnology applica-
tions [12,14]. Many viral particles are in the nanometer
size range and are naturally uniform in size because of the
structural constraints on capsid assembly. An increasing
number of three-dimensional virus structures known to
atomic resolution paved the way for derivatization of
VBNPs with dyes, metals, peptides, proteins, and small
molecules and is being explored for generating novel
nanomaterials. In the last decade several VBNPs have
been examined for diverse applications such as templates
for material synthesis, platforms for polyvalent display,
electronic components, and drug targeting [14-19]. Typi-
cal characteristics for a VBNP platform qualification
include knowledge about its crystal structure, ability to
produce in substantial quantities, stability in a wide range
of pH, and suitability for genetic manipulation as well as
chemical bioconjugation. Viruses and virus-like particles
(VLPs) that have been developed for nanotechnology pur-
poses include bacteriophages (M13 and MS2 [16,20]),
plant viruses (cowpea mosaic virus (CPMV), cowpea chlo-
rotic mottle virus (CCMV) and tobacco mosaic
virus(TMV) [15,18,21,22]), an insect virus (flock house
virus [23]), and animal viruses (adenovirus, polyoma
virus [24,25]). While infectious plant viral particles can be
produced in large quantities, generating substantial
amounts of most animal viruses in cell culture systems is
not economical. However, production of VLPs in ade-
quate quantities has been achieved by expression of virus
capsid proteins in heterologous systems (insect cells,
yeast, and bacteria). VLPs are generally found to be struc-
turally identical to native virus particles and more impor-
tantly are non-infectious. Viral particles are also being
explored as tumor targeting agents. Since most of the
established VBNPs do not have any specificity for tumor
cells and therefore need to be either genetically or chemi-
cally modified in order to achieve targeted delivery. These
targeting strategies are typically not as efficient when com-
pared to the natural cell receptor targeting potential of a
virus.
In this study we characterized canine parvovirus (CPV)-
VLPs as a potential nanomaterial for tumor targeting pur-
poses. CPV, a viral pathogen of canids (dogs) belongs to
the family parvoviridae  [26]. The infectious agent is an
icosahedral (T = 1), non-enveloped virus encapsidating a
single stranded DNA of about 5 kb and shows an average
diameter of 26.4 nm. The viral DNA encodes three
polypeptides VP1, VP2 and VP3 that are generated by
alternative splicing of viral mRNA. The crystal structure of
the virion revealed that a full (DNA-containing) capsid is
composed of 60 subunits, primarily of the VP2 subunits
(64 kDa) and a few VP1 and VP3 subunits. While empty
CPV Capsid and subunit organization Figure 1
CPV Capsid and subunit organization. The 2CAS model of CPV was downloaded from the VIPER database. The 
expanded inset shows a single VP2 subunit ribbon diagram with N-terminus in blue and C-terminus in red. B. Accessible sur-
face lysines profile of CPV capsid. Data shown was downloaded from VIPER database. Lysine residues in the VP2 subunit 
are shown on X-axis (total of 20 per subunit) and the effective radius multiplied by the solvent accessible surface area (SASA) 
is shown in blue on Y-axis on the left side. The radial distance of each residue is also shown on Y-axis in magenta. Coinciding 
high values on Y-axis suggest residues that are (i) highly accessible, (ii) moderately accessible and (iii) accessible to a lesser 
extent.Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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capsids contain mostly VP2 subunits along with a minor
amount of VP1 subunits but lack VP3 subunits [26]. Each
subunit is made up of a central 'jelly roll' anti-parallel β-
barrel core with elaborate loops between the β-strands
(Figure 1A) [26]. Generation of CPV-VLPs in both mam-
malian cells and insects cells by expressing only the VP2
gene has been described previously [27]. The transferrin
receptor (TfR) on canine cells serves as a cellular receptor
for the native CPV [28]. Interestingly, infectious CPV par-
ticles were also found to bind and enter human cells uti-
lizing TfRs, however, subsequent steps in the replication
cycle did not appear to be supported [28].
Transferrin is a circulatory iron carrier protein that is in
great demand particularly during cellular growth and pro-
liferation [29]. Since iron is also required by rapidly divid-
ing cancerous cells, a significant upregulation of
transferrin receptor expression is seen in a wide variety of
tumor cells. Indeed, analysis of TfR expression revealed
approximately 105 or more receptors per cell in several
breast cancer cell lines (including MDA-MB-231) [30],
HeLa (human cervical carcinoma) [31], HT-29 (human
colon carcinoma cells) [32], K562 (human erythroleuke-
mia cells) [31,33] and pancreatic tumor cells [34] com-
pared to a few or often undetectable TfR levels in normal
cells [35]. Therefore tagging a drug or image contrast agent
to transferrin for specific delivery to tumor cells emerged
as a promising strategy and is being widely explored for
tumor-targeted delivery [35,36]. Thus CPV-VLPs that bind
to human TfRs may hold an advantage over other viral
nanoparticles for tumor-specific delivery.
In this study we examined the suitability of CPV-VLPs for
tumor-targeting applications such as chemical modifica-
tion with small molecules and capability to deliver those
molecules to the tumor cells. CPV-VLPs produced in a
baculovirus expression system were analyzed for the
accessibility and chemical reactivity of capsid surface-
exposed lysines for derivatization with fluorescent dye
molecules. Binding and internalization of dye-derivatized
CPV-VLPs in various human tumor cells was investigated.
Results and discussion
For generation of CPV-VLPs, a recombinant baculovirus
expressing the full length CPV-VP2 gene (encoding 584
amino acids) under the control of the polyhedrin pro-
moter was utilized to infect insect cells as described previ-
ously [27]. In this study, however, instead of Sf-9 cells we
utilized insect T.ni cells for production of VLPs as they are
known for enhanced protein production. T.ni  cells
infected with recombinant baculovirus were harvested at
different time points (daily from between one through
five days) to optimize the yield of CPV-VLPs. An incuba-
tion length of 72–96 hrs post-infection was found to be
optimal for maximizing the yield. The VLP yields ranged
from 0.5 to 2 mg/ liter of infected T.ni cell culture. Harvest
of cells before 48 hrs or after 5 days post-infection reduced
the VLP yield to less than 50% of a 3–4 day harvest. While
early harvest suffered from inefficient infection, late har-
vest presumably leads to cell lysis releasing VLPs that seem
to be vulnerable to cell- or baculovirus-derived proteases
(data not shown). It was previously shown that although
a large amount of CPV-VP2 protein could be expressed
within Sf-9 insect cells, a portion of VP2 fails to assemble
into VLPs [27]. During a native parvovirus infection,
approximately 50% of the assembled capsids were found
to be empty (non-infectious) and composed primarily of
VP2 subunits with a few VP1 subunits [26]. Since the VP2
protein alone was expressed in the current study, a co-
expression of VP2 and VP1 in the baculovirus expression
system may enhance the assembly process and thereby
improve the yield of CPV-VLPs. Closely related porcine
parvovirus-VLPs appear to assemble more efficiently than
CPV in the baculovirus expression system as their yields
were substantial, approximately 120 mg/liter of culture in
a bioreactor [37]. VLPs of polyoma virus [38], hepatitis B
virus surface antigen [39], hepatitis delta virus [40] and
CCMV [41] have also been produced in large quantities in
a yeast expression system that may be useful for generat-
ing CPV-VLPs.
To evaluate whether CPV-VLPs could be efficiently deriva-
tized by chemical methods as has been performed for sev-
eral viral nanoparticles [14], the location of surface lysines
on CPV-VLPs was identified based upon a structural
model of CPV using the radial distance and solvent acces-
sibility surface area parameters in the VIPER database as
described in the methods. Based on the analyses, lysines
at positions 89 and 312 are highly accessible while those
Space filling model of surface accessible lysines on CPV cap- sid Figure 2
Space filling model of surface accessible lysines on 
CPV capsid. The CPV capsid model was generated with 
VMD software. The figure shows identified accessible lysines 
on CPV based upon the whole capsid (left side) and on an 
individual VP2 subunit (right side).Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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at positions 163 and 387 are moderately accessible and
those at positions 570 and 575 on the particle surface are
accessible to lesser extent (Figure 1B). Using this model,
two (maximum of 6) lysines of the twenty lysines per VP2
subunit, or 120 (maximal of 360) lysines per CPV-VLP
particle could theoretically be accessible on the capsid sur-
face for bioconjugation. However, the reactivities are
known to vary from their predicted accessibility based
upon the local chemical environment of the lysine residue
on the capsid surface [15]. Surface accessible lysines on
the capsid and on a single subunit of VP2 are depicted in
a space filling model in Figure 2. Immediately following
purification, the CPV-VLPs were examined for reactivity
and conjugation to the lysines by exposure to NHS-Ore-
gon Green 488 (OG-488). In most cases, using 100 molar
equivalents of OG-488 dye molecules per VP2 subunit in
the VLP preparation, an average of 45 lysines/particle were
addressed. Exposure to 200 molar equivalents of the dye
per VP2 subunit resulted in an average of 100 derivatized
lysines/particle. Further increase in the dye equivalents
did not appear to enhance CPV-VLP labeling (data not
shown). Initially, the virus labeling was carried out in a
phosphate buffer (0.1 M potassium phosphate) similar to
dye derivatization of CPMV [15]. The CPV-VLP particles,
although stable in phosphate buffer, could not withstand
the presence of additional 10% DMSO and a dye, which
caused disassembly of the VLPs into subunits. In contrast
CPMV particles are known to withstand such labeling
environment [15]. Performing dye labeling of CPV-VLPs
in PBSE buffer, or in phosphate buffer containing 150
mM sodium chloride stabilized the particles (data not
shown).
To characterize the CPV-VLPs from the infected T.ni cell
culture, particles were centrifuged in a 10–40% sucrose
gradient. The VLPs formed two bands visible about the
middle of the tube (data not shown). A hazy smeared
upper band presumably represented a mixture of empty
CPV purification and characterization Figure 3
CPV purification and characterization. A. Sucrose gradient purification. VLPs preparation from infected cell culture 
lysates purified by sucrose gradient centrifugation (10–40%). Bands of CPV-VLPs that were derivatized with OG-488 are visible 
in the gradient just above the middle of the tube (left panel) and appear fluorescent green under a UV-light source (right panel). 
B. SDS-PAGE analyses. The purified VLPs were subjected to electrophoresis in 4–12% Bis-tris gel and stained with Simply-
Blue (Invitrogen) to reveal the proteins (left panel). The Seeblue plus protein molecular weight standards in kDa (Invitrogen) 
are indicated on the side of the gel picture (lane 1). Lanes 2 and 3 contain protein from CPV-VLPs derivatized with OG-488 
and CPV-VLPs respectively. Prior to staining, the gel (right panel) visualized with a UV-light source showed a fluorescent 62 
kDa band in the lane of OG-488 derivatized CPV-VLPs (lane 2f) and lacked any fluorescent bands in the native CPV-VLPs (lane 
3f).Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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particles (lacking nucleic acids) and particles with variable
amounts of nucleic acids. The lower faint band we
hypothesized was comprised of particles with a definite
amount of randomly packaged cellular nucleic acid mate-
rial. The proportions of these bands varied greatly over
each preparation. The packaging of non-specific cellular
nucleic acids into VLPs during baculovirus expression has
been described [42]. The smeared VLP bands in the gradi-
ent also suggested VLP preparation has packaged variable
amounts of nucleic acids that are most likely random cel-
lular RNA since the particles assemble in the cytoplasm
(data not shown). Gradient purified VLP preparation was
collected and analyzed by SDS-PAGE for presence of viral
coat protein and to evaluate sample purity. The gel
revealed a 62 kDa protein corresponding to the known
molecular weight of CPV-VP2 protein (Figure 3B) with no
obvious degradation products or impurities. The differ-
ence in VP2 gene product to an expected 64 kDa is pre-
sumed to be due variation in gel mobilities of proteins.
Similar to unlabeled particles, CPV-VLP particles labeled
with the dye OG-488 when separated on the gradient
revealed a smeared top band and another band about the
Capsid stability and morphology of CPV-VLPs Figure 4
Capsid stability and morphology of CPV-VLPs. A and B. Size exclusion chromatography (SEC) of CPV-VLPs. 
Sucrose gradient purified samples were passed through a Superose6 size exclusion column. Absorbance values recorded at 260 
nm (for nucleic acids), 280 nm (for protein) and 496 nm (for OG-488 dye) are shown on the y-axis. The elution profile from 
the column in ml is shown on x-axis. Panel A shows SEC of freshly purified CPV-VLPs and panel B shows SEC of CPV-VLPs 
labeled with OG-488 dye following 1 week of storage at 4°C. C and D. Electron micrographs of CPV-VLPs. CPV-VLPs 
were deposited onto carbon-coated copper grids and stained with uranyl acetate. The micrographs of (C) full capsids in a 
freshly purified CPV-VLPs preparation and (D) empty capsids in CPV-VLPs sample after 1 week of storage are shown. Both 
micrographs were taken at a nominal magnification of 60,000×.Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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middle of the gradient, similar to that of a native CPV-VLP
preparation (Figure 3A left panel). The band appeared flu-
orescent when exposed to a UV- light source (Figure 3A,
right panel). Dye-derivatized CPV-VLPs, when analyzed
on SDS-PAGE showed a fluorescent band upon exposure
to a UV-light source that migrated at 62 kDa. No differ-
ence was observed in the mobility of the dye-derivatized
CPV-VP2 subunit protein compared to native CPV-VP2
subunit protein under the SDS-PAGE conditions used, as
expected since there are an estimated 1 to 2 molecules of
OG-488 dye per VP2 subunit (with approximate increase
of about 0.6 to 1.2 kDa; Figure 3B).
The sucrose gradient-purified particles were analyzed by
size exclusion chromatography (SEC) for elution volume
and absorbance indicative of particle size, intactness and
packaged nucleic acid material. SEC of a freshly purified
VLP preparation revealed that the absorbance at 260 nm
was high compared to absorbance at 280 nm (Figure 4A)
suggestive of packaged nucleic acids. With a flow rate of
0.4 ml/min in PBSE buffer (pH 7.4), the particles had elu-
tion volume of 11–13 ml on the SEC column. Cowpea
mosaic virus particles (approximately 31 nm in diameter)
that are routinely used our laboratory showed an elution
of 8 to 10 ml in PBSE buffer (data not shown) on the same
column suggested that the CPV-VLPs (26 nm-sized) are
smaller in size and intact. Disassociated or unassembled
subunits and other contaminant proteins showed elution
volumes greater than 15 ml. Surprisingly, containment of
nucleic acid material within CPV-VLPs was transitory, as
the particles were found to be empty after one to two days
of storage at 4°C. After a week of storage at 4°C the parti-
cles exhibited a lower absorbance at 260 nm indicating
lack of nucleic acid material (Figure 4B). Presumably the
packaged nucleic acid was hydrolyzed. Finding entirely
empty particles immediately following purification was
also not uncommon. Although empty, the CPV-VLPs were
found to be quite stable in PBSE buffer after several
months of storage at 4°C without showing any signs of
disassembly. The particle intactness could be confirmed
over the SEC column and by transmission electron micro-
scopy (TEM) (data not shown). Analyses of dye-labeled
particles on the SEC at 496 nm revealed that the conjugate
dye molecules are associated with the intact VLPs (Figure
4B). TEM analyses of purified VLPs supported the obser-
vation that the particles were not empty initially following
purification. Figure 4C shows the CPV-VLP capsids with
an electron-dense core indicating the presence of nucleic
acid. In contrast, after 7 days of storage the particles have
an electron-opaque core consistent with empty capsids
(Figure 4D). Interestingly, expression of coat proteins
from the RNA viruses, FHV coat protein [42] or tomato
bushy stunt virus [43] in the baculovirus system results in
VLPs containing variable amounts of cellular RNA. How-
ever, this packaged cellular RNA is not lost upon storage.
Presumably, as a DNA-containing virus, the CPV capsid
interior has natural affinity for viral single-stranded DNA
and therefore lacks the capability to retain any of the non-
specifically packaged RNA, resulting in empty particles
eventually.
Previous studies have revealed that the native CPV utilizes
canine as well as human TfRs to internalize and reach the
endosomes in cells [28]. Detailed analyses of CPV capsid
Binding and internalization into of CPV-VLPs into HeLa cells Figure 5
Binding and internalization into of CPV-VLPs into HeLa cells. HeLa cells incubated with Texas red-labeled transferrin 
(red) and CPV-VLPs were washed and fixed. Labeled antibodies (green) were used to detect the presence of CPV-VLPs in the 
cells by fluorescence confocal microscopy. (A) CPV-VLPs are seen as green areas in the cytoplasm, (B) shows localization of 
Texas Red-transferrin (red) and (C) depicts merged picture showing co-localization of CPV-VLPs and transferrin in yellow. 
Scale bar, 25 µm.Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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revealed that the Asn residues at positions 93 and 300 on
the three fold spike are important in binding to the canine
TfRs. Additionally, several residues in the shoulder region
(Gly 299, Lys 387, Ala 300, Thr 301, and val 316) also
appear to play a role in binding [44]. Based on the CPV-
capsid modeling (Figure 1B) the Lys residues at positions
89 and 312 are the most solvent accessible and therefore
more likely to be derivatized. In our bioconjugation
experiments, attachment of dyes to the Lys 387 residue in
some of the subunits cannot be ruled out. However, the
role of these residues in CPV binding specifically to
human TfRs has not been determined.
Once it was demonstrated that CPV-VLPs could withstand
chemical conjugation and remain intact following purifi-
cation, the dye-labeled CPV-VLPs were investigated for
their potential utility to target tumor cells. First we exam-
ined the binding and internalization of CPV-VLPs into
HeLa tumor cells that over-express TfRs [31] (Figure 5).
The internalization of CPV-VLP particles was fairly rapid,
occurring within two hours as previously observed with
native CPV [28]. Co-localization of the antibodies recog-
nizing CPV-VLPs with Texas red-labeled transferrin con-
firmed that the VLPs are localized to endosomes following
uptake. Confocal image analyses showed approximately
50–60 % co-localization, and the differences seen are
likely due to fact that Tfn is efficiently recycled while CPV
particles are diverted from endosomes to lysosomes, con-
sistent with previous reports [28,45]. Binding to TfRs and
clathrin-mediated vesicular trafficking of CPV to endo-
somes and lysosomes in the cells has been demonstrated
previously in HeLa cells and in non-cancerous NLFK cells
[28,45]. We next examined whether CPV-VLPs derivatized
with OG-488 dye molecules will show a similar cell bind-
ing and internalization characteristics. To confirm the TfR
specificity, the binding of OG-488-labeled CPV-VLPs to
TRVb1 cells (expressing TfR), and TRVb cells (lacking or
expressing very low levels of TfR) [46] was investigated.
The binding and internalization of dye-labeled CPV-VLPs
was observed only in the TRVb1 cells but not in TRVb cells
(Figure 6) confirming that binding and internalization is
TfR-mediated. Thus the TfR-specific internalization of
OG-488 labeled CPV-VLPs is similar to the native CPV-vir-
ions, in agreement with an earlier report [28]. Since CPV-
VLPs could efficiently enter HeLa tumor cells and the dye-
labeled CPV-VLPs demonstrated TfR specificity, we then
examined binding and internalization of OG-488-labeled
CPV-VLPs into other human tumor cell lines that are
known to over-express TfRs such as HT-29 and MDA-
MB231 cells [30,31]. The CPV-VLPs derivatized with OG-
488 were taken up by all three cell lines investigated
within 2 hours, similar to unlabeled particles in HeLa cells
(Figure 7).
Thus we have demonstrated that CPV-VLPs, derivatized
with small molecules to the lysines on the capsid surface,
retain their targeting for TfRs. Furthermore, CPV-VLPs can
withstand the conditions required for chemical modifica-
tion expanding their utility for conjugation with chemo-
therapeutic drugs or image contrast agents. Our future
efforts are directed towards tumor targeting with dye and
drug-labeled VLPs in mouse models of human cancer.
Derivatization of CPV-VLPs with chemotherapeutic drugs
conjugated via various kinds of endosomal cleavable link-
ers [8,47] is being investigated for release of the drug spe-
cifically into the tumor cell interior. While there are many
kinds of nanoparticles in development for tumor targeting
[6], VBNPs compared to their peers, exhibit remarkable
uniformity and offer precise control over display of mole-
cules. Achieving this level of control over spatial distribu-
tion is unparalleled with inorganic or lipid nanomaterial.
However, since VLPs are proteinaceous in composition,
an immune response by the host is obvious, limiting their
usage for repeat administration. Utilizing multiple VLPs
or employing polymer coat shielding of particles [48,49]
or using altered chimeric particles [50] may address
immune clearance issues.
Conclusion
CPV-VLPs can be produced in significant quantities in the
baculovirus expression system. Optimization of the
expression including addition of other regions of capsid
proteins or truncated versions of VP2 gene or other sys-
tems of protein expression may be useful for further
improving the particle yield. Like native CPV, dye-labeled
CPV-VLPs specifically bind to TfRs known to be upregu-
Binding and internalization of CPV-VLPs labeled with OG- 488 into transferrin receptor expressing cells Figure 6
Binding and internalization of CPV-VLPs labeled with 
OG-488 into transferrin receptor expressing cells. 
Cells differing in level of transferrin receptor expression, 
TRVb1 (express TfRs) and TRVb (low or lacking TfR expres-
sion) were exposed to CPV-VLPs. Internalized dye-labeled 
CPV-VLPs were detected by fluorescence confocal micros-
copy. TOTO-3 (blue) was used for staining the nuclei. (A) 
TRVb1 cells with internalized dye-derivatized CPV-VLPs, are 
seen as green areas in the cytoplasm, and (B) TRVb cells 
show lack of VLP internalization. Scale bar, 25 µm.Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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lated on a variety of tumor cells. Derivatization of lysine
residues on CPV-VLPs with small molecules is feasible
under appropriate reaction conditions and does not inter-
fere with the binding and internalization into tumor cells.
Together these studies demonstrate the potential for
development of CPV-VLPs as a novel virus-based platform
for tumor targeted delivery of drugs and image contrast
agents.
Materials and methods
Production and purification of CPV-VLPs from insect cells
Recombinant baculovirus production of CPV-VLPs has
been previously described [27]. The recombinant virus
was a gift of Dr. C. Parrish (Cornell University, Ithaca,
New York). Initial stock preparation, plaque purification
and determination of plaque forming units (pfu) was per-
formed in Spodoptera frugiperda (Sf-21) cells. For large
scale preparations, Trichoplusia ni (T.ni) cells were propa-
gated at 27°C in EX-CELL 401serum-free medium (JRH
Biosciences, Lenexa, KS) supplemented with 2 mM L-
glutamine, 100 U/ml of penicillin per ml, and 100 µg/ml
of streptomycin. Each liter of culture containing 1 × 106
cells/ml was infected with 15 to 20 ml of recombinant
virus at a titer of 5 to 8 × 106 pfu/ml. Following incubation
of infected cells at 28°C and 100 rpm in shaker flask (typ-
ically for 72 hrs), cells were harvested by centrifugation at
1500 g for 10 mins. The cells were re-suspended in 100 ml
of phosphate buffered saline (PBS) containing 10 mM
ethylene diamine tetra acetic acid (PBSE, pH 7.4). The
cells were lysed by addition of Triton X-100 to a final con-
centration of 1% along with 2 mM phenylmethyl sulfonyl
fluoride on ice for 10 minutes. The cell debris was pelleted
by centrifugation at 10000 g for 30 mins. To the superna-
tant an equal volume of chloroform/butanol mixture
(1:1) was added and stirred for 15 mins at 4°C. The solu-
tion was centrifuged at 10000 g for 20 mins. The aqueous
supernatant was collected carefully and polyethylene gly-
col 8000 and sodium chloride were added to a final con-
centration of 8% and 400 mM respectively. The mixture
after stirring for 20 mins at 4°C was centrifuged at 15000
g for 20 mins. The pellet containing the CPV-VLPs was re-
suspended in 10 ml of PBSE. Following 30 minutes of
mixing on a shaker at room temperature, the suspension
was centrifuged at 9000 g to remove insoluble debris. The
supernatant comprising of the CPV-VLPs was transferred
to a tube containing 4 ml of 20% sucrose cushion in PBSE
and centrifuged in a 50.2 Ti rotor (Beckman, Fullerton,
CA) at 145,000 g for 3 hrs at 4°C. The pellet was resus-
pended in 1 ml of PBSE and then layered onto a 10–40%
sucrose gradient in PBSE, and centrifuged at 207000 g for
2 hrs in a SW41 rotor (Beckman) at 4°C. Bands visible
about the mid-point of tube were collected and centri-
fuged in 50.2Ti rotor at 145000 g for 3 hrs at 4°C. The col-
lected pellet comprising of purified CPV-VLPs was
resuspended in PBSE and stored at 4°C. Purified VLP sam-
ples were analyzed by sodium-dodecyl-sulfate polyacryla-
mide gel electrophoreses (SDS-PAGE), size exclusion
chromatography and transmission electron microscopy.
The yield of VLPs was quantitated using a Lowry protein
assay kit (Pierce, Rockford, IL).
CPV-VLPs denatured in SDS-PAGE sample buffer were
separated in a 4–12% bis-tris polyacrylamide gel (Invitro-
gen, Carlsbad, CA) by employing a 200 V constant current
for 35 minutes. The protein bands were visualized by
staining with Simply Blue (Invitrogen). For dye-labeled
Binding and internalization of CPV-VLPs labeled with OG-488 into tumor cell lines Figure 7
Binding and internalization of CPV-VLPs labeled with OG-488 into tumor cell lines. Tumor cell lines (A) HeLa, (B) 
HT-29 and (C) MDA-MB231 were exposed to OG488-labeled CVP-VLPs. The cells were washed, fixed and examined by con-
focal fluorescence microscopy for internalization of the particles. Scale bar, 25 µm.Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
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virus (see below), following electrophoresis the gel was
placed on a UV-light box to visualize fluorescent bands.
SEC was carried out on a Superose6 column using an
AKTA explorer (Amersham-Pharmacia Biotech, Piscata-
way, NJ) with a flow rate of 0.4 ml/minute in PBSE buffer
(pH7.4).
CPV-VLP modeling
The CPV-VLP capsid structure (Figure 1A,B) was obtained
from the virus particle explorer database (VIPER) [51].
The model shown was rendered with CHIMERA software
[52]. The inset in figure 1A shows a ribbon diagram of a
single VP2 protein subunit. The accessible lysines on the
capsid surface were determined based on the radial dis-
tance of the residue, effective radius and solvent accessible
surface area of CPV-VLPs in VIPER database that was orig-
inally determined using CHARMM software [53]. The
identified surface accessible lysines were then represented
in a space filling model of CPV-VLPs designed using Vis-
ual Molecular Dynamics software (VMD) [54].
Dye labeling of CPV-VLPs
Based on previously published methods for dye labeling
of the plant virus CPMV [15], CPV in PBSE was labeled
with various molar equivalents of the dye, Oregon green-
488 succinimidyl ester (OG-488, Invitrogen). Briefly, OG-
488 dye (MWr = 662.5) was added to100 or 200 molar
equilvalents per VP2 subunit (MWr = 64000) as follows.
First the dye was dissolved in dimethyl sulfoxide (DMSO)
and then mixed with virus in PBSE to contain not more
than 10% of DMSO final concentration. A virus concen-
tration of 2 mg/ml in PBSE was used for all dye labeling
reactions. Following overnight incubation at room tem-
perature, hydroxalamine (pH 8.5) was added to a final
concentration of 1.5 M to inactivate the dye ester. The dye-
labeled virus was sucrose gradient purified as described
above. The collected virus band was further dialyzed with
3 exchanges against PBSE. The amount of dye conjugated
onto the VLPs calculated as absorbance measured at 496
nm times the molecular weight of virus (64000 × 60)
divided by the product of extinction coefficient of OG-
488 dye (70000) and concentration of virus in mg/ml.
VLPs derivatized with the dye were analyzed by SDS-
PAGE, SEC and TEM. The binding and internalization of
dye-labeled CPV-VLP in TRVb, TRVb1 and tumor cells was
examined by confocal microscopy.
Cell lines
Human tumor cell lines, HT-29, HeLa and MDA-MB231
were obtained from American Type Culture Collection
(Manassas, VA). HT-29 was maintained in Leibovitz
medium (Invitrogen) while HeLa and MDA-MB231 were
cultured in modified DMEM (Invitrogen). Chinese ham-
ster ovarian cells TRVb (negative for transferrin receptor
expression) and TRVb1 (derived from TRVb cells contain-
ing an expression plasmid for human transferrin receptor)
have been previously described (gift of Dr. T. Mc Graw,
Cornell University) [46] and were maintained in Ham's F-
10 medium (Invitrogen) without or with 0.2 mg/ml of
geneticin (Invitrogen) respectively. Each of the culture
media containing L-glutamine described above was sup-
plemented with 10% fetal bovine serum, and antibiotics
penicillin (100 U/ml) and streptomycin (100 µg/ml).
Confocal and electron microscopy
Approximately 10,000 cells/well of HeLa cells were plated
in a 12-well tissue culture plate containing circular glass
cover slips. After overnight incubation, the cells were
exposed to either 10 µg/ml of Texas red-labeled transferrin
(Invitrogen) or 20 µg/ml of CPV-VLPs or both (for co-
localization studies) for 2 hrs at 37°C in media without
serum. Following incubation the cells were washed 3
times with media and then fixed with ice-cold 4% parafor-
maldehyde in PBS (pH 7.4) for 10 mins. After fixing, the
cells were washed 3 times with PBS and then treated for 10
mins in PBS containing 0.1% Triton X-100 and 1% bovine
serum albumin (permeabilization buffer). The cells were
exposed to rabbit anti-CPV antibodies (1:500) diluted in
permeabilization buffer for 1 hr at room temperature. The
cells were washed three times in PBS and exposed to
Alexa-488 labeled goat anti-rabbit antibodies (Invitrogen)
at a dilution of 1:2000 in permeabilization buffer for 30
mins at room temperature. The cover slips were washed
three times with PBS then quickly with water prior to
mounting with Vectashield hard set medium (Vector Lab-
oratories, Burlingame, CA) on glass slides. The cells were
examined with a Zeiss Axiovert Confocal microscope. For
experiments with TRVb, TRVb1 and various tumor cells,
each of the cell line was exposed to OG488-CPV-VLP
under similar conditions as described above. Addition-
ally, TRVb cells were treated with TOTO-3 (Invitrogen) for
nuclear staining. Following fixation the cells were washed
with PBS and directly visualized by confocal microscopy.
Transmission electron microscopic analyses of CPV-VLPs
were performed by depositing 10 µl aliquots of sample
onto 100-mesh carbon-coated copper grids for 2 minutes.
The grids were then stained with 10 µl of 2% uranyl ace-
tate and visualized under a Philips CM100 electron micro-
scope.
Authors' contributions
PS conceived the study and performed experiments. GD
assisted with dye labeling, virus structural modeling and
column chromatography analyses. AS assisted with the
baculovirus expression system and virus purification. MM
provided guidance with the experimental design and
manuscript preparation. All authors read and approved
the final manuscript.Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
Page 10 of 11
(page number not for citation purposes)
Acknowledgements
We thank C. Hsu and Dr. W. Ochoa for assistance with electron micros-
copy. The authors acknowledge the help of Dr. V. Reddy (TSRI) in CPV 
virus capsid modeling. We appreciate the generous gift of baculovirus 
recombinant expressing CPV-VP2 protein and TRVb1 cells by Drs. C. Par-
rish and T. McGraw respectively at Cornell University, New York. This 
work presented in this TSRI manuscript #17725-CB was supported by 
grants CA112075 and NO1-CO-27181 to M.M. and A.S.
References
1. Fennelly D: Dose intensity in advanced ovarian cancer: have
we answered the question?  Clin Cancer Res 1995, 1:575-582.
2. Myers CE, Chabner BA: Anthracyclins.  In Cancer chemotherapy-prin-
ciples and practice Edited by: Chabner, B. A., Collins, J. M.. Philadelphia,
Lippincott; 1990:256-381. 
3. Dubowchik GM, Walker MA: Receptor-mediated and enzyme-
dependent targeting of cytotoxic anticancer drugs.  Pharmacol
Ther 1999, 83:67-123.
4. Feng SS, Chien S: Chemotherapeutic engineering: application
and further development of chemical engineering principles
for chemotherapy of cancer and other diseases.  Chemical Engi-
neering Science 2003, 58:4087-4114.
5. Brannon-Peppas L, Blanchette JO: Nanoparticle and targeted sys-
tems for cancer therapy.  Advanced drug delivery reviews 2004,
56:1649-1659.
6. Ferrari M: Cancer nanotechnology: opportunities and chal-
lenges.  Nat Rev Cancer 2005, 5:161-171.
7. Medina OP, Zhu Y, Kairemo K: Targeted liposomal drug delivery
in cancer.  Curr Pharm Des 2004, 10:2981-2989.
8. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny C.G,
Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco
JA, Wahl AF, Meyer DL, Senter PD: Development of potent mon-
oclonal antibody auristatin conjugates for cancer therapy.
Nat Biotechnol 2003, 21:778-784.
9. Muldoon L.L., Neuwelt EA: BR96-DOX immunoconjugate tar-
geting of chemotherapy in brain tumor models.  J Neurooncol
2003, 65:49-62.
10. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simp-
son JC, Lord JM, Taylor-Robinson AW, Stockley PG: RNA bacteri-
ophage capsid-mediated drug delivery and epitope
presentation.  Intervirology 2002, 45:371-380.
11. Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CM, Thies MJ,
Walter J, Weigand M, Woith DC, Hess J, Reiser CO: Efficient intra-
cellular delivery of a protein and a low molecular weight sub-
stance via recombinant polyomavirus-like particles.  J Biol
Chem 2004, 279:27410-27421.
12. Pattenden LK, Middelberg AP, Niebert M, Lipin DI: Towards the
preparative and large-scale precision manufacture of virus-
like particles.  Trends Biotechnol 2005, 23(10):523-529.
13. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ,
Thomas TP, Balogh LP, Khan MK, Baker JRJ: Nanoparticle target-
ing of anticancer drug improves therapeutic response in ani-
mal model of human epithelial cancer.  Cancer Res 2005,
65:5317-5324.
14. Singh P, Gonzalez MJ, Manchester M: Viruses and their uses in
nanotechnology.  Drug Development Research 2006.
15. Wang Q, Kaltgrad E, Lin T, Johnson JE, Finn MG: Natural supramo-
lecular building blocks:  wild-type cowpea mosaic virus.  Chem
Biol 2002, 9(7):805-811.
16. Peabody DS: A viral platform for chemical modification and
multivalent display.  J Nanobiotechnology 2003, 1:5.
17. Hooker JM, Kovacs EW, Francis MB: Interior surface modifica-
tion of bacteriophage MS2.  J Am Chem Soc 2004, 126:3718-3719.
18. Basu G, Allen M, Willits D, Young M, Douglas T: Metal binding to
cowpea chlorotic mottle virus using terbium(III) fluores-
cence.  J Biol Inorg Chem 2003, 8:721-725.
19. Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG:
Accelerated bioorthogonal cojugation: A practical method
for ligation of diverse functional molecules to a polyvalent
virus scaffold.  Bioconj Chem 2005, 16(6):1572-1579.
20. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R:
Design and validation of a bifunctional ligand display system
for receptor targeting.  Chemistry & Biology 2004, 11:1081-1091.
21. Chatterji A, Ochoa W, Paine M, Ratna BR, Johnson JE, Lin T: New
Addresses on an addressable virus nanoblock: uniquely reac-
tive lys residues on cowpea mosaic virus.  Chemistry and Biology
2004, 11:855-863.
22. Chatterji A, Ochoa W, Shamieh L, Salakian SP, Wong SM, Clingon G,
Ghosh P, Lint T, Johnson J: Chemical conjugation of heterolo-
gous proteins on the surface of cowpea mosaic virus.  Biocon-
jug Chem 2004, 15:807-813.
23. Portney NG, Singh K, Chaudhary. S., Destito G, Schneemann A, Man-
chester M, Ozkan M: Organic and inorganic nanoparticle
hybrids.  Langmuir 2005, 21:2098-2103.
24. Henning P, Andersson KM, Frykholm K, Ali A, Magnusson MK,
Nygren PA, Granio O, Hong SS, Boulanger P, Lindholm L: Tumor
cell targeted gene delivery by adenovirus 5 vectors carrying
knobless fibers with antibody-binding domains.  Gene Ther
2005, 12:211-224.
25. Gleiter S, Lilie H: Cell-type specific targeting and gene expres-
sion using a variant of polyoma VP1 virus-like particles.  Biol
Chem 2003, 384:.
26. Tsao J, Chapman MS, Agbandje M, Keller W, Smith K, Wu H, Luo M,
Smith TJ, Rossmann MG, Compans RW, Parrish CR: The three-
dimensional structure of canine parvovirus and its functional
implications.  Science 1991, 251:1456-1464.
27. Yuan W, Parrish CR: Canine parvovirus capsid assembly and
differences in mammalian and insect cells.  Virology 2001,
279:546-557.
28. Parker JS, Murphy WJ, Wang D, O'Brien SJ, Parrish CR: Canine and
feline parvoviruses can use human or feline transferrin
receptors to bind, enter, and infect cells.  J Virol 2001,
75:3896-3902.
29. Gomme PT, McCann KB, Bertolini. J: Transferrin: structure, func-
tion and potential therapeutic actions.  Drug Discov Today 2005,
10:267-273.
30. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL: Differ-
ences in transferrin response and numbers of transferrin
receptors in rat and human mammary carcinoma lines of dif-
ferent metastatic potentials.  J Cell Physiol 1993, 156:212-217.
31. Bridges KR, Smith BR: Discordance between transferrin recep-
tor expression and susceptibility to lysis by natural killer
cells.  J Clin Invest 1985, 76:913-918.
32. Becker A, Riefke B, Ebert B, Sukowski U, Rinneberg H, Semmler W,
Licha K: Macromolecular contrast agents for optical imaging
of tumors: comparison of indotricarbocyanine-labeled
human serum albumin and transferrin.  Photochem Photobiol
2000, 72:234-241.
33. Sato Y, Yamauchi N, Takahashi M, Sasaki K, Fukaura J, Neda H, Fujii
S, Hirayama M, Itoh Y, Koshita Y, Kogawa K, Kato J, Sakamaki S,
Niitsu Y: In vivo gene delivery to tumor cells by transferrin-
streptavidin-DNA conjugate.  FASEB J 2000, 14:2108-2118.
34. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J:
Transferrin receptor is a marker of malignant phenotype in
human pancreatic cancer and in neuroendocrine carcinoma
of the pancreas.  Eur J Cancer 2004, 40:1418-1422.
35. Qian Z, Li H, Sun H, Ho K: Targeted drug delivery via the trans-
ferrin receptor-mediated endocytosis pathway.  Pharm Rev
2002, 54:561-587.
36. Hogemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson
L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP: The trans-
ferrin receptor: a potential molecular imaging marker for
human cancer.  Neoplasia 2003, 5:495-506.
37. Maranga L, Rueda P, Antonis AF, Vela C, Langeveld, J.P., Casal JI, Car-
rondo MJ: Large scale production and downstream processing
of a recombinant porcine parvovirus vaccine.  Appl Microbiol
Biotechnol 2002, 59:45-50.
38. Sasnauskas K, Bulavaite A, Hale A, Jin L, Knowles WA, Gedvilaite A,
Dargeviciute A, Bartkeviciute D, Zvirbliene A, Staniulis J, Brown DW,
Ulrich R: Generation of recombinant virus-like particles of
human and non-human polyomaviruses in yeast Saccharo-
myces cerevisiae.  Intervirology 2002, 45:308-317.
39. Li HZ, Gang HY, Sun QM, Liu X, Ma YB, Sun MS, Dai CB: Produc-
tion in Pichia pastoris and characterization of genetic engi-
neered chimeric HBV/HEV virus-like particles.  Chin Med Sci J
2004, 19:78-83.
40. Wu HL, Chen PJ, Mu JJ, Chi WK, Kao TL, Hwang LH, Chen DS:
Assembly of hepatitis delta virus-like empty particles in
yeast.  Virology 1997, 236:374-381.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Nanobiotechnology 2006, 4:2 http://www.jnanobiotechnology.com/content/4/1/2
Page 11 of 11
(page number not for citation purposes)
41. Brumfield S, Willits D, Tang L, Johnson JE, Douglas T, Young M: Het-
erologous expression of the modified coat protein of Cow-
pea chlorotic mottle bromovirus results in the assembly of
protein cages with altered architectures and function.  J Gen
Virol 2004, 85:1049-1053.
42. Krishna NK, Marshall D, Schneemann A: Analysis of RNA packag-
ing in wild-type and mosaic protein capsids of flock house
virus using recombinant baculovirus vectors.  Virology 2003,
305:10-24.
43. Hsu C, Singh P, Ochoa W, Manayani DJ, Schneeman A, Reddy V:
Characterization of polymorphism displayed by the coat
protein mutants of tomato bushy stunt virus.  Virology
2006:manuscript accepted.
44. Parker JS, Parrish CR: Canine parvovirus host range is deter-
mined by the specific conformation of an additional region of
the capsid.  J Virol 1997, 71:9214-9222.
45. Suikkanen S, Saajarvi K, Hirsimaki J, Valilehto O, Reunanen H, Vihinen-
Ranta M, Vuento M: Role of recycling endosomes and lyso-
somes in dynein-dependent entry of canine parvovirus.  J Virol
2002, 76:4401-4411.
46. McGraw TE, Greenfield L, Maxfield FR: Functional expression of
the human transferrin receptor cDNA in Chinese hamster
ovary cells deficient in endogenous transferrin receptor.  J
Cell Biol 1987, 105:207-214.
47. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S,
Sinko PJ, Stein S, Farmanfarmaian A, Minko T: Tumor-specific tar-
geting of an anticancer drug delivery system by LHRH pep-
tide.  Proc Natl Acad Sci U S A 2005, 102:12962-12967.
48. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R,
Hermiston T, Ulbrich K, Fisher KD, Seymour LW: Extended
plasma circulation time and decreased toxicity of polymer-
coated adenovirus.  Gene Ther 2004, 11:1256-1263.
49. Raja KS, Wang Q, Gonzalez MJ, Manchester M, Johnson JE, Finn MG:
Hybrid virus-polymer materials. 1. Synthesis and properties
of PEG-decorated cowpea mosaic virus.  Biomacromolecules
2003, 4:472-476.
50. Netter HJ, Woo WP, Tindle R, Macfarlan RI, Gowans EJ: Immuno-
genicity of recombinant HBsAg/HCV particles in mice pre-
immunised with hepatitis B virus-specific vaccine.  Vaccine
2003, 21:2692-2697.
51. Reddy VS, Natarajan P, Okerberg B, Li K, Damodaran KV, Morton
RT, Brooks CL, Johnson JE: Virus Particle Explorer (VIPER), a
website for virus capsid structures and their computational
analyses.  http://viperdb.scripps.edu.  J Virol 2001,
75:11943-11947.
52. http://www.chimera.org.  .
53. Brooks B, Bruccoleri B, Olafson D, States D, Swaminathan S, Karplus
M: CHARMM: a program for macromolecular energy, mini-
mization and dynamics calculation.  J Comp Chem 1983,
4:183-217.
54. http://www.ks.uiuc.edu/Research/vmd.  .